Patrick Brannelly is the founding CEO of The 10,000 Brains Project, a philanthropic initiative that supports the ethical use of AI in the development of better treatments for Alzheimer's, Parkinson’s, and other neurodegenerative diseases. He has nearly 20 years of experience building groundbreaking neuroscience initiatives.

Most recently, Brannelly was a member of the Health & Life Sciences team at Gates Ventures, where he served as the Director of Partnerships & Business Development for the Alzheimer’s Disease Data Initiative. Prior to this, he was the Managing Director of the Rainwater Charitable Foundation’s Tau Consortium, which seeks to accelerate the development of new treatments for Alzheimer’s disease and frontotemporal dementia.

Earlier in his career, Brannelly was the CEO of NeoCORTA and the Director of Partnerships & Group Programs at Posit Science, both early-stage brain health technology ventures. He has also served in the US and Europe as a management consultant in the pharmaceutical, energy, and technology sectors. A frequent member of boards and committees, Brannelly is a Board member of Stroke Onward, a Steering Committee member of the OECD’s Neuroscience-Inspired Policy Initiative, and an Advisory Board member of the Applied Neuroscience Association.

Brannelly holds a BA in Psychology from Harvard College, an MBA with Distinction from Harvard Business School, and an MSc in Applied Neuroscience with Distinction from King’s College London. A believer in the importance of lifelong learning, Brannelly is currently pursuing a professional certificate in Machine Learning and Artificial Intelligence at the University of California, Berkeley. He is a former Assistant Professor of entrepreneurship and strategy at California State University.

Milken Institute, CEO, Chief Executive Officer (CEO), Philanthropy, Alzheimers, Alzheimer's Disease, Artificial Intelligence, Parkinson's Disease, Neuroscience, Neurological Disorder, Machine Learning Health,